1763 Stock Overview
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
China Isotope & Radiation Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.32 |
| 52 Week High | HK$19.24 |
| 52 Week Low | HK$9.03 |
| Beta | 0.70 |
| 1 Month Change | -11.64% |
| 3 Month Change | -10.73% |
| 1 Year Change | -37.23% |
| 3 Year Change | -63.92% |
| 5 Year Change | -50.50% |
| Change since IPO | -48.66% |
Recent News & Updates
Recent updates
China Isotope & Radiation (HKG:1763) Has A Rock Solid Balance Sheet
Mar 28
There Are Reasons To Feel Uneasy About China Isotope & Radiation's (HKG:1763) Returns On Capital
May 13Is Now The Time To Look At Buying China Isotope & Radiation Corporation (HKG:1763)?
Feb 07China Isotope & Radiation (HKG:1763) Will Want To Turn Around Its Return Trends
Dec 20A Look At The Intrinsic Value Of China Isotope & Radiation Corporation (HKG:1763)
Oct 28China Isotope & Radiation (HKG:1763) Seems To Use Debt Quite Sensibly
Sep 30There Are Reasons To Feel Uneasy About China Isotope & Radiation's (HKG:1763) Returns On Capital
Aug 30Is There Now An Opportunity In China Isotope & Radiation Corporation (HKG:1763)?
Jun 10China Isotope & Radiation (HKG:1763) Could Easily Take On More Debt
Apr 11Is It Time To Consider Buying China Isotope & Radiation Corporation (HKG:1763)?
Dec 28China Isotope & Radiation (HKG:1763) Seems To Use Debt Quite Sensibly
Oct 26Capital Allocation Trends At China Isotope & Radiation (HKG:1763) Aren't Ideal
Oct 08Is Now An Opportune Moment To Examine China Isotope & Radiation Corporation (HKG:1763)?
Sep 05Returns On Capital At China Isotope & Radiation (HKG:1763) Paint A Concerning Picture
Jun 13When Should You Buy China Isotope & Radiation Corporation (HKG:1763)?
May 24China Isotope & Radiation (HKG:1763) Has A Pretty Healthy Balance Sheet
Apr 01Our Take On The Returns On Capital At China Isotope & Radiation (HKG:1763)
Mar 14The China Isotope & Radiation (HKG:1763) Share Price Has Gained 24% And Shareholders Are Hoping For More
Feb 04
Is Now The Time To Look At Buying China Isotope & Radiation Corporation (HKG:1763)?
Jan 09Will China Isotope & Radiation (HKG:1763) Multiply In Value Going Forward?
Dec 14China Isotope & Radiation Corporation's (HKG:1763) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Nov 23Shareholder Returns
| 1763 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 10.1% | -3.6% | -0.7% |
| 1Y | -37.2% | -53.2% | -13.4% |
Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned -53.2% over the past year.
Return vs Market: 1763 underperformed the Hong Kong Market which returned -13.4% over the past year.
Price Volatility
| 1763 volatility | |
|---|---|
| 1763 Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1763 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1763's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 3,105 | Hongchao Xu | www.china-isotope.com |
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits.
China Isotope & Radiation Corporation Fundamentals Summary
| 1763 fundamental statistics | |
|---|---|
| Market cap | HK$3.30b |
| Earnings (TTM) | HK$401.13m |
| Revenue (TTM) | HK$7.17b |
8.2x
P/E Ratio0.5x
P/S RatioIs 1763 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1763 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.63b |
| Cost of Revenue | CN¥3.15b |
| Gross Profit | CN¥3.48b |
| Other Expenses | CN¥3.11b |
| Earnings | CN¥370.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.16 |
| Gross Margin | 52.48% |
| Net Profit Margin | 5.59% |
| Debt/Equity Ratio | 23.0% |
How did 1763 perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield27%
Payout RatioDoes 1763 pay a reliable dividends?
See 1763 dividend history and benchmarks| China Isotope & Radiation dividend dates | |
|---|---|
| Ex Dividend Date | Jun 12 2024 |
| Dividend Pay Date | Aug 06 2024 |
| Days until Ex dividend | 49 days |
| Days until Dividend pay date | 104 days |
Does 1763 pay a reliable dividends?
See 1763 dividend history and benchmarks